We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

11 hedge funds and large institutions have $4.26M invested in Moleculin Biotech in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.11% less ownership

Funds ownership: 10.29% → 10.17% (-0.11%)

8% less funds holding

Funds holding: 12 → 11 (-1)

28% less capital inflows, than outflows

Capital inflows: $234K | Capital outflows: $327K

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
11
Holders Change
-1
Holders Change %
-8.33%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$140K
2
BlackRock
BlackRock
New York
+$46.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$46.8K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$140K
2
Whitegate Investment Counselors
Whitegate Investment Counselors
New Hampshire
-$46.8K
3
Jane Street
Jane Street
New York
-$42K
4
ARTA
A.R.T. Advisors
New York
-$31K
5
HRT Financial
HRT Financial
New York
-$22K

MBRX Hedge Fund Activity: Q4 2019 in Review

11 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2019, worth a combined $4.26M — down 17% from $5.16M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of MBRX and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $140K. The largest seller was Millennium Management, cutting an estimated $140K.

  • 11 institutional investors held Moleculin Biotech (MBRX) as of Q4 2019, down from 12 in Q3 2019.
  • Funds reported $4.26M of Moleculin Biotech stock for Q4 2019, down 17% quarter-over-quarter.
  • 1 fund opened new Moleculin Biotech positions in Q4 2019 and 2 closed out, a net change of -1 holder.
  • The largest Moleculin Biotech buyer in Q4 2019 was Susquehanna International Group, an estimated $140K added.
  • The largest Moleculin Biotech seller in Q4 2019 was Millennium Management, an estimated $140K sold.

Based on aggregated 13F filings for Q4 2019.